REGENXBIO Investors Have Opportunity to Join Investigation with Schall Law Firm

The Schall Law Firm is investigating claims against REGENXBIO Inc. (RGNX) for alleged securities law violations. The investigation focuses on whether the company issued false or misleading statements and/or failed to disclose information relevant to investors. Shares of RGNX fell 17.9% after the FDA placed a clinical hold on two of its investigational gene therapies. Investors who suffered losses can contact the Schall Law Firm for free consultation and potential participation in the investigation.